Gilead Sciences, Inc. (GILD) CEO Discusses Q2 2013 Results - Earnings Call ... Seeking Alpha Another presentation was on the combination use of idelalisib and rituximab in elderly treatment naive CLL SLL patients. In this study, the overall response rate was 97% and the Kaplan-Meier estimate of progression-free survival at 24 months was 93%. |
